ALDEYRA THERAPEUTICS INC (ALDX)

Aldeyra Therapeutics CEO Todd C. Brady reported buying 250,000 ALDX shares at a $1.6738 weighted average price, lifting his direct stake to 1,721,298 shares.

Todd C Brady, Director, President and CEO, on June 03, 2026, executed a purchase for 250,000 shares in Aldeyra Therapeutics for $418,450. Following the Form 4 filing with the SEC, Brady has...

See Forward Earnings Fair Value & Price Prediction → · Valuation Analysis: ALDX is currently trading at $1.70, which is considered extended relative to its 30-day fair value range of $1.57 to $1.75. From a valuation perspective, the stock is trading at a discount (Forward PE: -9.8) compared ...

Todd C. Brady, President and CEO of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), acquired a significant block of the company’s common stock, according to a recent SEC filing.

Insight Molecular (NASDAQ:IMDX) stock rose 13.16% to $5.93. The market value of their outstanding shares is at $211.5 million. Bio Green Med Solution (NASDAQ:BGMS) shares moved upwards by 11.99% to $1.68. The market value of their outstanding shares is at $5.8 million. Shattuck Labs (NASDAQ:STTK) sh…